FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response	S)														
1. Name and Address of Reporting Person* Katkin Keith				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner					
(Last) (First) (Middle) C/O RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/12/2017						-	Officer (give	e title below)	Other	(specify below)		
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(Cit	y)	(State)	(Zip)			Ta	ble I	- Non-Deri	vative Secu	urities	Acquire	d, Disposed	of, or Bene	ficially Owned	I	
1.Title of S (Instr. 3)	Date			2A. Dec Execution any (Month)	on Dat	e, if C	3. Transaction Code Instr. 8)		4. Securities Acqu (A) or Disposed of (Instr. 3, 4 and 5)		of (D) Owned Follow			d OFO	wnership orm: Be irect (D) Ov Indirect (Ir	Nature Indirect eneficial wnership astr. 4)
							Code	e V A	,	(D) or	Price			(I)	nstr. 4)	
								in this t	orm are r	ot re	quired to	o respond	unless the	tion containe e form	d SEC 14'	74 (9-02)
			Table II -					in this f	form are r s a curre	not rently v	equired to alid OME	o respond 3 control n	unless the		d SEC 14 ⁷	74 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if	4. Transac Code	tion of Officers	s, warr Numb	er ative es d (A) sed	in this to display uired, Disposortions, co	form are rest a current of sed of, or nvertible servisable and Date	not rently v Benefaccuri	equired to alid OME ficially Ov ties)	o respond 3 control n wned nd Amount ying	unless the umber.		10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	tion of Officers	Numb Deriva ecuritie equired Dispo (D) nstr. 3,	er ative es d (A) sed 4,	in this to display uired, Dispositions, conficulty 6. Date Exercises	s a current of sea of sea of, or nvertible sercisable and Date y/Year)	Benefsecuri	ricially Over ties) 7. Title arof Underly Securities	o respond 3 control n wned nd Amount ying	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indirec Beneficia Ownersh

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Katkin Keith C/O RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X					

Signatures

/s/ Dolly Vance (Attorney-in-Fact)	05/12/2017
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares vest monthly over twelve (12) months from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.